Skyviews Life Science
VC Fund
Lausanne, Switzerland
Skyviews Life Science is a privately held advisory company specializing in personalized health. Skyviews Life Science identifies investment opportunities in companies at the growing interface between biotechnology, advanced nutrition, and digital health.Skyviews Life Science focuses in private and public companies with better drugs, advancedtechnology platforms, preventive strategies, personalized solutions, and more natural foods that will improve people’s quality of life.
- Total investments:
- 14
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Skyviews Life Science invests in
Stages Skyviews Life Science invests in
Countries Skyviews Life Science invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $4.5M–$27M
- Series B
- $29M–$105M
Investment Focus
Industry
- Biotechnology 8 (57%)
- Life Science 4 (29%)
- Medical 3 (21%)
- Health Care 3 (21%)
- Food and Beverage 3 (21%)
Stage
- Series B 5 (36%)
- Series A 2 (14%)
- Seed 1 (7%)
- Series C 1 (7%)
- Series D 1 (7%)
Country
- United States 4 (29%)
- Switzerland 2 (14%)
- United Kingdom 2 (14%)
- Israel 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Boris F. J. Collardi
Founding investor
|
Founding investor | Total investments: 0 | Find email | |
|
Jean-Pierre Aoun
Co-Founder and General Partner
|
Co-Founder and General Partner | Total investments: 0 | Find email | |
R. Anthony Williamson
Partner Biotechnology and Health Science
|
Partner Biotechnology and Health Science | Total investments: 0 | Find email | |
Stefan Catsicas
Co-Founder and Managing Partner
|
Co-Founder and Managing Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| BCD Bioscience is an emerging biotechnology spinout from UC Davis that creates ingredients for food and biopharmaceutical applications. The company was founded in 2019 and is headquartered in Davis, California, United States. | $27M / Series A / Dec 12, 2024 | ||
| Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $106.5M / Series E / Apr 25, 2023 | ||
| Volumina is active in the field of tissue engineering and develops injectable 3D scaffolds for the reconstruction of volumes of soft tissues (fat, muscles, glandular tissues, supporting and connective tissues) that have been lost after tumor ablation, disease, trauma, or for purely esthetically purposes. | Series A / Oct 04, 2022 | ||
| At Tropic Biosciences, They develop high-performing commercial varieties of tropical crops which promote grower wellbeing, consumer health, and improved sustainable environmental practices, using cutting edge non-GMO gene editing techniques. | $35M / Series C / Jul 06, 2022 | ||
| BCD Bioscience is an emerging biotechnology spinout from UC Davis that creates ingredients for food and biopharmaceutical applications. The company was founded in 2019 and is headquartered in Davis, California, United States. | $12M / Series A / Apr 13, 2022 | ||
| Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $68M / Series D / Jul 21, 2021 | ||
| Aleph Farms is an Israel-based food technology company designing new ways to grow quality animal products that improve sustainability, food security and animal welfare in our food systems. Founded in 2017, the company utilized cellular agriculture technology to unveil the world’s first cultivated thin-cut steak in 2018, the world’s first cultivatedribeye steak in 2021, and cultivated collagen in 2022. Under its product brand, Aleph Cuts, the company will launch its first product, the Petit Steak, grown from the non-modified cells of a premium Angus cow. For its contributions to climate leadership including a net zero commitment made in 2020, it has received top accolades from the World Economic Forum and the United Nations. | $105M / Series B / Jul 07, 2021 | ||
| Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $82M / Series B / May 05, 2021 | ||
| Mirai Foods is a cellular agriculture startup developing cultured beef. | $4.5M / Seed / Mar 15, 2021 | ||
| Ukko is a biotech firm focused on creating safe immunotherapies for quickly addressing allergies and other immune-related disorders. The company utilizes a unique technology platform that combines computational protein design with mRNA/LNP delivery to alter allergenic proteins. This approach seeks to mitigate or eliminate the risks of severeallergic reactions while eliciting a protective immune response. The Company is focused on changing the approach to prevent allergic reactions at the molecular level, striving to offer a safer and more targeted alternative to conventional desensitization techniques. This will lessen the treatment burden while meeting the critical needs of those vulnerable to severe allergic reactions to peanuts, with possibilities for extending the solution to other major allergens like milk, tree nuts, and respiratory triggers. | $40M / Series B / Jan 27, 2021 | ||
| See all 14 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Skyviews Life Science invest in?
Skyviews Life Science invests primarily in Biotechnology, Life Science and Medical startups, most often at Series B and Series A stage. Most of the 14 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Skyviews Life Science's check size?
Skyviews Life Science typically joins rounds of $4.5M–$27M at Series A and $29M–$105M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Skyviews Life Science participates in.
How do I contact Skyviews Life Science?
Public channels for Skyviews Life Science include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Skyviews Life Science?
The team at Skyviews Life Science includes Boris F. J. Collardi (Founding investor), Jean-Pierre Aoun (Co-Founder and General Partner) and R. Anthony Williamson (Partner Biotechnology and Health Science). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
